Journal of geriatric psychiatry and neurology · 2025
Efficacy and Safety of Novel Continuous Subcutaneous Levodopa Infusion Therapies ND0612 and ABBV-951 for Parkinson's Disease: A Systematic Review.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fernandes Matheus de Medeiros, Nogueira Luis Otávio Souza, Rabelo Isabella Soares Marques, Dallé Louise Dalla Corte, Corso Angela Maria Sandini, Santos Fernanda Medeiros, Pinto Roberta Arb Saba Rodrigues, Borges Vanderci, Ferraz Henrique Ballalai, Boone Dayany Leonel
Аннотация
IntroductionRecent research in Parkinson's disease (PD) has highlighted the potential therapies of continuous subcutaneous infusions (CSCI) of levodopa/carbidopa (ND0612) and foslevodopa/foscarbidopa (ABBV-951). This systematic review aims to explore their effectiveness and safety for PD.MethodsGuided by the PRISMA statement, we systematically searched 3 electronic databases: MEDLINE, Embase, and Cochrane Central. We combined quantitative and qualitative data for synthesis and descriptive analysis. Quality assessment and risk of bias were evaluated by ROBINS-1 and Rob-2 criteria.ResultsWe included 6 records with a total of 698 patients. CSCI therapies reduced motor symptoms in PD patients with levodopa-related motor fluctuations and clinical improvements. Infusions-site reactions were the main adverse event recorded.ConclusionsND0612 and ABBV-951 are promising options for enhancing motor control and quality of life in PD patients. However, further research is needed to assess long-term efficacy, safety, and comparisons with oral levodopa and device-aided treatments.